Overview

Elocon vs Fluticasone in Localized Psoriasis (P03197)

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Schering-Plough
Treatments:
Fluticasone
Mometasone Furoate